September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The effect of dexamethasone implant ( Ozurdex®) on anterior chamber parameters in patients with retinal vein occlusion
Author Affiliations & Notes
  • Berna Akova Budak
    Ophthalmology, Uludag University, Bursa, Turkey
  • Sertac Argun Kivanc
    Ophthalmology, Uludag University, Bursa, Turkey
  • Sami Yilmaz
    Retina Eye Hospital, Bursa, Turkey
  • Berkant Kaderli
    Ophthalmology, Uludag University, Bursa, Turkey
  • Ozgur Yalcinbayir
    Ophthalmology, Uludag University, Bursa, Turkey
  • Mehmet Baykara
    Ophthalmology, Uludag University, Bursa, Turkey
  • Ahmet Ali Yucel
    Ophthalmology, Uludag University, Bursa, Turkey
  • Footnotes
    Commercial Relationships   Berna Akova Budak, None; Sertac Argun Kivanc, None; Sami Yilmaz, None; Berkant Kaderli, None; Ozgur Yalcinbayir, None; Mehmet Baykara, None; Ahmet Yucel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Berna Akova Budak, Sertac Argun Kivanc, Sami Yilmaz, Berkant Kaderli, Ozgur Yalcinbayir, Mehmet Baykara, Ahmet Ali Yucel; The effect of dexamethasone implant ( Ozurdex®) on anterior chamber parameters in patients with retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the effects of dexamethasone implant ( Ozurdex®) on anterior chamber parameters and choroidal thickness in patients with retinal vein occlusion.

Methods : This retrospective study comprised 65 patients with central retinal vein (CRVO) or branch retinal vein occlusion (BRVO) complicated with macular edema who had Ozurdex® injection. The patients with diabetes, glaucoma and history of any ocular surgery were excluded. Thirty-six patients (18 females,18 males) with a mean age of 62±9.1 years and with at least 6 months follow up were evaluated. All the patients underwent ophthalmologic examination including visual acuity measurement, biomicroscopy and indirect funduscopy. In all patients, Pentacam® (Oculus, Germany) was used as an anterior segment tomographer to assess corneal volume (CV) , central corneal thickness ( CCT), anterior chamber volume (ACV) and anterior chamber depth before dexamethasone injection and at 1st and 3rd months after injection. OCT (Spectralis, Heidelberg) was performed before dexamethasone injection and at 1st and 3rd months after injection for retinal nerve fiber layer, central macular (CMT) and choroidal thickness (CT) measurement .

Results : Eight patients had CRVO and 28 had BRVO. In 61 % of the patients right eyes were involved and all the eyes were phakic. Regarding CCT and CV, there was no significant difference between pre-injection measurement and the others at 1st and 3rd month ( CCT as 547±37 µ, 547±43 and 547±40 respectively and CV as 58±5mm3 , 58±5 mm3 and 59±5 mm3 respectively). There was significant difference between pre-injection and post injection measures of ACV at 1st and 3rd month ( 127±24 mm3 ,144±25 mm3 , 155±26 mm3 , p<0.001). CMT and CT values at 1st and 3rd months were found to be significantly lower than pre-injection values ( for CMT p<0,001 at 1st month, p=0.03 at 3rd month; for CT p=0.001 at 1st month, p=0.001 at 3rd month).

Conclusions : Intravitreal Ozurdex injection may also change anterior segment parameters while significantly decreasing CMT and CT. This finding should be taken into account during follow up.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×